Understanding how certain immune cells affect tuberculosis
Elucidating the mechanisms and consequences of MDSC-regulated immunity in TB
This study is looking at how certain immune cells called myeloid-derived suppressor cells (MDSCs) affect tuberculosis (TB) and how they might change the way we treat the disease, with the hope of finding better therapies for people with TB.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10857265 on NIH RePORTER |
What this research studies
This research investigates the role of myeloid-derived suppressor cells (MDSCs) in tuberculosis (TB) and how they may influence the disease's severity and treatment outcomes. By examining the interactions between MDSCs and other immune cells, the study aims to uncover mechanisms that could lead to improved therapies for TB. The research involves both animal models and human samples to explore how MDSCs affect the immune response to TB and the effectiveness of vaccinations like BCG. The ultimate goal is to identify potential new treatment strategies that target these immune cells to enhance TB management.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those experiencing severe symptoms or complications.
Not a fit: Patients with non-infectious respiratory conditions or those who do not have tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for tuberculosis, potentially improving recovery rates and reducing disease severity.
How similar studies have performed: Previous studies have shown promising results in animal models regarding the targeting of MDSCs to improve TB treatment, indicating potential for success in human applications.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Mattila, Joshua T. — University of Pittsburgh at Pittsburgh
- Study coordinator: Mattila, Joshua T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.